MetaVia’s (MTVA) “Buy” Rating Reiterated at HC Wainwright

MetaVia (NASDAQ:MTVAGet Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock.

MetaVia Stock Performance

NASDAQ MTVA opened at $1.55 on Friday. MetaVia has a 1-year low of $1.29 and a 1-year high of $5.30. The stock has a fifty day moving average of $1.71.

About MetaVia

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Read More

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.